Core Points - Maase Inc. has executed a definitive share purchase agreement to issue 10,000,000 Class A ordinary shares at a price of $2.08 per share, generating approximately $21 million in gross proceeds [1][3] - The transaction includes warrants for an additional 20,000,000 Class A ordinary shares, with exercise prices structured in two tranches: 50% at 200% of the purchase price and 50% at 250% [2] - Upon closing, the largest investor will hold about 19.29% of the total outstanding shares, translating to 0.73% of the voting power due to the dual-class share structure [2] Financial Details - The total number of ordinary shares outstanding after the transaction will be 25,917,241, comprising 19,250,573 Class A and 6,666,668 Class B shares [2] - The net proceeds from the share issuance will be used for business plans, general working capital, and other corporate purposes [3] Company Background - Maase Inc., founded in 2010, aims to be a leading provider of technology-driven family and enterprise services, focusing on enhancing quality of life through technological intelligence and capital investments [6] - The company holds controlling interests in two financial service providers in China: AIFU Inc. and Puyi Fund Distribution Co., Ltd. [7]

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) -- Sable Resources Ltd. (“Sable” or the “Company”) (TSXV:SAE | OTCQB:SBLRF) is pleased to announce that Moxico Resources plc (“Moxico”) has agreed to acquire a 9.9% ownership stake in the Company through the purchase of 31,800,000 common shares (“Shares”) at C$0.055 per Share for a total subscription of C$1,749,000 (the “Private Placement”), subject to ...

Core Points - Indaptus Therapeutics, Inc. has raised a total of $5.7 million through the sale of convertible promissory notes and accompanying warrants [1][2] - The notes have a 6% annual interest rate and will mature on July 28, 2026, with conversion into common stock at a price equal to 80% of the average Nasdaq closing price for the five trading days prior to conversion, capped at $11.20 [2] - Warrants to purchase 200% of the conversion shares will be issued upon conversion, with an exercise price equal to the conversion price and a term of five years [3] - The net proceeds from the offering will be used for research and development activities, including funding a Phase 1b/2 clinical trial, as well as for working capital and general corporate purposes [4]

Core Viewpoint - American Tungsten Corp. is proceeding with a non-brokered private placement to raise up to $2,500,000 through the sale of 5,000,000 common shares at $0.50 per share, aimed at accelerating the development of the IMA Tungsten Project and enhancing its position in the North American tungsten supply chain [1][2]. Group 1: Offering Details - The private placement will involve the issuance of up to 5,000,000 common shares at a price of $0.50 per share, generating gross proceeds of up to $2,500,000 [1]. - The company will pay finders' fees of up to 7.0% of the gross proceeds and issue non-transferable finders' warrants equal to 7.0% of the shares sold, allowing the holder to acquire shares at $0.50 for up to 24 months [3]. - The closing of the offering is contingent upon receiving necessary corporate and regulatory approvals, and there is no minimum subscription amount required [5]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund exploration work programs, option payments, mineral property acquisitions, marketing, and general working capital [4]. Group 3: Company Overview - American Tungsten Corp. is focused on tungsten and magnetite exploration in North America, particularly advancing the IMA Mine Project in Idaho, which has a historical production background [7]. - The company holds an option to acquire full ownership of the IMA Mine Project, subject to a 2% royalty, and has expanded its land position with 113 additional federal claims covering nearly 2,000 acres [7].

Core Points - Quantum Critical Metals Corp. has closed the first tranche of its non-brokered private placement financing, raising gross proceeds of $1,029,100 through the sale of 10,291,000 units at a price of $0.10 per unit [1] - Each unit consists of one common share and one common share purchase warrant, with warrants allowing the purchase of shares at $0.20 until June 27, 2027 [1] - The net proceeds will be used for exploration activities in British Columbia and Quebec, as well as for general corporate purposes [2] Group 1 - The closing of the offering is subject to final approval from the TSX Venture Exchange and other customary conditions [3] - A second and final tranche is expected to close around July 13, 2024, with securities issued subject to a four-month hold period expiring on October 28, 2025 [3] - Finder's fees included $42,387 in cash and 422,870 broker warrants for subscriptions introduced by certain persons [4] Group 2 - Certain insiders participated in this tranche, making it a "related party transaction" under Multilateral Instrument 61-101, exempt from formal valuation and minority shareholder approval [5] - Insiders contributed $100,000 in the first tranche through the issuance of 1,000,000 units [5] Group 3 - The company has a diverse portfolio of assets, including projects in gallium, rubidium, cesium, antimony, copper, and germanium, positioning it to support the transition to a sustainable critical minerals supply [8]

Core Viewpoint - Quantum BioPharma Ltd. is completing a non-brokered private placement of class A multiple voting shares at a price of $50 per share, aiming for gross proceeds of up to $600 million, expected to be fully subscribed by existing holders of MVS [1][3]. Group 1: Offering Details - The Offering consists of class A multiple voting shares priced at $50 each, with total gross proceeds anticipated to reach $600 million [1]. - All securities issued in the Offering are subject to a statutory hold period of four months plus a day from issuance, in accordance with Canadian securities laws [2]. - The proceeds from the Offering will be utilized for general working capital purposes [2]. Group 2: Insider Participation - The Offering is expected to be fully subscribed by Xorax Family Trust and Fortius Research and Trading Corp., both of which have insider connections to the Company [3]. - The participation of these insiders is classified as a "related-party transaction" under Multilateral Instrument 61-101, with exemptions from formal valuation and minority shareholder approval requirements being relied upon [3]. Group 3: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [6]. - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [6]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc. and is entitled to royalty payments of 7% on sales until reaching $250 million, after which the royalty rate will decrease to 3% [6].

Core Viewpoint - Titan Pharmaceuticals, Inc. has completed a private placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management for a total of $600,000, with a conversion price set at $3.40 [1] Group 1: Private Placement Details - Blue Harbour purchased 60,000 shares of Preferred Stock for an aggregate purchase price of $600,000 [1] - The shares have a conversion price of $3.40 [1] - The transaction does not involve a public offering and has not been registered under the Securities Act of 1933 [3] Group 2: Ownership and Conversion Restrictions - The Certificate of Designations includes a beneficial ownership conversion "blocker" preventing Blue Harbour from acquiring more than 19.99% of the Company's outstanding common stock without shareholder approval [2] Group 3: Advisory and Agreements - ARC Group Ltd. served as the sole financial advisor to Titan in this private placement [4] - Titan and Blue Harbour have entered into a Registration Rights Agreement, which provides certain registration rights under specified conditions [3]

Core Viewpoint - Critical One Energy Inc. has successfully closed a non-brokered financing, raising CDN$1,000,000 through the issuance of 2,500,000 units at CDN$0.40 per unit, which will be utilized for exploration activities and general expenses [1][4]. Financing Details - The financing involved the issuance of units, each consisting of one common share and one-half common share purchase warrant, with full warrants allowing the purchase of one common share at CDN$0.60 for 18 months [2]. - A director participated in the financing, acquiring 230,000 units for a total of CDN$92,000, qualifying as a related party transaction [2][3]. Regulatory Compliance - The company relied on exemptions from valuation and minority approval requirements under Multilateral Instrument 61-101, as the transaction did not exceed 25% of the company's market capitalization [3]. Use of Proceeds - Proceeds from the private placement are earmarked for exploration activities at the Howells Lake Antimony Gold Project and for general administrative expenses [4]. Company Overview - Critical One Energy Inc. focuses on critical minerals and upstream energy, with a strategic position to meet the rising global demand for critical minerals, particularly through its antimony-gold exploration in Canada and uranium interests in Namibia [5].

Core Viewpoint - XORTX Therapeutics Inc. is conducting a non-brokered private placement to raise up to USD $925,000 through the issuance of common share units, aimed at advancing its programs for gout and progressive kidney disease [1][5]. Group 1: Offering Details - The private placement will involve the issuance of up to 1,267,123 common share units at a price of USD $0.73 per unit, each unit consisting of one common share and one common share purchase warrant [1]. - Each warrant will allow the holder to purchase an additional common share at USD $1.20, valid for 60 months from the closing date, with an acceleration clause if the common shares exceed USD $2.00 for 10 consecutive trading days [1]. Group 2: Regulatory Compliance - The offering will be available to purchasers in Canada, excluding Quebec, under the Listed Issuer Financing Exemption, meaning the securities will not be subject to a hold period under Canadian securities laws [2]. - The offering document related to the placement can be accessed on the company's profile and website, and prospective investors are encouraged to review it before making investment decisions [3]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized to advance XORTX's programs for gout and for general corporate purposes [5]. Group 4: Company Overview - XORTX Therapeutics Inc. is focused on developing innovative therapies for gout and progressive kidney disease, with three clinically advanced products: XRx-026 for gout, XRx-008 for ADPKD, and XRx-101 for acute kidney injury [6]. - The company is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy, targeting purine metabolism and xanthine oxidase to reduce uric acid production [6].

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- Mustang Energy Corp. (CSE: MEC, OTC: MECPF, FRA: 92T) (“Mustang” or the “Company”) is pleased to announce a non-brokered private placement (the “Offering”) for aggregate gross proceeds of up to C$3,000,000 from the sale of any combination of the following: non-flow through units of the Company (each, a “Unit”) at a price of C$0.14 per Unit;critical ...